HDAC6 inhibitors increase efficacy of immunotherapy in triple-negative breast cancer
 

Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published in the top-tier journal Cancer Research by investigators at the George Washington University (GW) Cancer Center.

More...